Pfizer Inc. (PFE) said the U.S. Food and Drug Administration declined to approve an application to market the antidepressant Pristiq as a treatment for certain menopausal symptoms such as hot flashes. The New York-based drug maker said in a statement on its website Sept. 8 it had received
